"I provide comprehensive psychiatric evaluations, individual, couples and family psychotherapy, and medication management for adults, adolescents and children and their families. I use multimodal ...
Agreement will allow further development of Resolvin-based therapy. Celtic Therapeutics has acquired and licensed worldwide rights to Resolvyx’s RX-10045, a late-stage program for the treatment of dry ...
Resolvyx Pharmaceuticals announced positive data from its Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye ...
BEDFORD, Mass.--(BUSINESS WIRE)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin ...
Resolvyx announces positive phase 2 trial of Resolvin RX-10045 in patients with dry eye syndrome ...
BEDFORD, MA –August, 24, 2009 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results